References

The Revised Authoritative Guide To Vaccine Legal Exemptions

Vaccines Have Serious Side Effects

Get Instant Access

1. Kiessling, R., Klein, E., Pross, H., and Wigzell, H. (1975). "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. European journal of immunology 5, 117-121.

2. Kiessling, R., Klein, E., and Wigzell, H. (1975). "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. European journal of immunology 5, 112-117.

3. Colucci, F., Caligiuri, M.A., and Di Santo, J.P. (2003). What does it take to make a natural killer? Nature reviews 3, 413-425.

4. Di Santo, J.P. (2006). Natural killer cell developmental pathways: a question of balance. Annual review of immunology 24, 257-286.

5. Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M.C., Biassoni, R., and Moretta, L. (2001). Activating receptors and coreceptors involved in human natural killer cellmediated cytolysis. Annual review of immunology 19, 197-223.

6. Bottino, C., Castriconi, R., Moretta, L., and Moretta, A. (2005). Cellular ligands of activating NK receptors. Trends in immunology 26, 221-226.

7. Tassi, I., Klesney-Tait, J., and Colonna, M. (2006). Dissecting natural killer cell activation pathways through analysis of genetic mutations in human and mouse. Immunological reviews 214, 92-105.

8. Kagi, D., Ledermann, B., Burki, K., Seiler, P., Odermatt, B., Olsen, K.J., Podack, E.R., Zinkernagel, R.M., and Hengartner, H. (1994). Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369, 31-37.

9. Clementi, R., Locatelli, F., Dupre, L., Garaventa, A., Emmi, L., Bregni, M., Cefalo, G., Moretta, A., Danesino, C., Comis, M., et al. (2005). A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood 105, 4424-4428.

10. Martin-Fontecha, A., Thomsen, L.L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A., and Sallusto, F. (2004). Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nature immunology 5, 1260-1265.

11. Hanna, J., Gonen-Gross, T., Fitchett, J., Rowe, T., Daniels, M., Arnon, T.I., Gazit, R., Joseph, A., Schjetne, K.W., Steinle, A., et al. (2004). Novel APC-like properties of human NK cells directly regulate T cell activation. The journal of clinical investigation 114, 1612-1623.

12. Moretta, L., Bottino, C., Pende, D., Vitale, M., Mingari, M.C., and Moretta, A. (2005). Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunology letters 100, 7-13.

13. Nedvetzki, S., Sowinski, S., Eagle, R.A., Harris, J., Vely, F., Pende, D., Trowsdale, J., Vivier, E., Gordon, S., and Davis, D.M. (2007). Reciprocal regulation of natural killer cells and macrophages associated with distinct immune synapses. Blood.

14. Schleypen, J.S., Von Geldern, M., Weiss, E.H., Kotzias, N., Rohrmann, K., Schendel, D.J., Falk, C.S., and Pohla, H. (2003). Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. International journal of cancer 106, 905-912.

15. Weinberg, R.A. (2006). The Biology of Cancer, 1st edn. (Garland Science).

16. Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M.A., Vallejo, C., Martos, J.A., and Moreno, M. (1997). The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79, 2320-2328.

17. Ishigami, S., Natsugoe, S., Tokuda, K., Nakajo, A., Che, X., Iwashige, H., Aridome, K., Hokita, S., and Aikou, T. (2000). Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88, 577-583.

18. Villegas, F.R., Coca, S., Villarrubia, V.G., Jimenez, R., Chillon, M.J., Jareno, J., Zuil, M., and Callol, L. (2002). Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung cancer 35, 23-28.

19. Lorenzen, J., Lewis, C.E., McCracken, D., Horak, E., Greenall, M., and McGee, J.O. (1991). Human tumour-associated NK cells secrete increased amounts of interferon-gamma and inter-leukin-4. British journal of cancer 64, 457-462.

20. Albertsson, P.A., Basse, P.H., Hokland, M., Goldfarb, R.H., Nagelkerke, J.F., Nannmark, U., and Kuppen, P.J. (2003). NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends in immunology 24, 603-609.

21. Hokland, M., Kjaergaard, J., Kuppen, P.J., Nannmark, U., Agger, R., Hokland, P., and Basse, P. (1999). Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. In vivo 13, 199-204.

22. Hanna, J., Wald, O., Goldman-Wohl, D., Prus, D., Markel, G., Gazit, R., Katz, G., Haimov-Kochman, R., Fujii, N., Yagel, S., et al. (2003). CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood 102, 1569-1577.

23. Ferlazzo, G., Pack, M., Thomas, D., Paludan, C., Schmid, D., Strowig, T., Bougras, G., Muller, W.A., Moretta, L., and Munz, C. (2004). Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proceedings of the national academy of sciences of the United States of America 101, 16606-16611.

24. Romagnani, C., Della Chiesa, M., Kohler, S., Moewes, B., Radbruch, A., Moretta, L., Moretta, A., and Thiel, A. (2005). Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. European journal of immunology 35, 2452-2458.

25. Moller, M.J., Kammerer, R., and von Kleist, S. (1998). A distinct distribution of natural killer cell subgroups in human tissues and blood. International journal of cancer 78, 533-538.

26. Jonges, L.E., Albertsson, P., van Vlierberghe, R.L., Ensink, N.G., Johansson, B.R., van de Velde, C.J., Fleuren, G.J., Nannmark, U., and Kuppen, P.J. (2001). The phenotypic heterogeneity of human natural killer cells: presence of at least 48 different subsets in the peripheral blood. Scandinavian journal of immunology 53, 103-110.

27. Gazit, R., Gruda, R., Elboim, M., Arnon, T.I., Katz, G., Achdout, H., Hanna, J., Qimron, U., Landau, G., Greenbaum, E., et al. (2006). Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nature immunology 7, 517-523.

28. Kim, S., Iizuka, K., Kang, H.S., Dokun, A., French, A.R., Greco, S., and Yokoyama, W.M. (2002). In vivo developmental stages in murine natural killer cell maturation. Nature immunology 3, 523-528.

29. Tsuchiyama, J., Yoshino, T., Toba, K., Harada, N., Nishiuchi, R., Akagi, T., Furukawa, T., Takahashi, M., Fuse, I., Aizawa, Y., and Harada, M. (2002). Induction and characterization of cutaneous lymphocyte antigen on natural killer cells. British journal of haematology 118, 654-662.

30. Imai, T., Hieshima, K., Haskell, C., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T.J., and Yoshie, O. (1997). Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91, 521-530.

31. Xin, H., Kikuchi, T., Andarini, S., Ohkouchi, S., Suzuki, T., Nukiwa, T., Huqun, Hagiwara, K., Honjo, T., and Saijo, Y. (2005). Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. European journal of immunology 35, 1371-1380.

32. Al-Atrash, G., Shetty, S., Idell, S., Xue, Y., Kitson, R.P., Halady, P.K., and Goldfarb, R.H. (2002). IL-2-mediated upregulation of uPA and uPAR in natural killer cells. Biochemical and biophysical research communications 292, 184-189.

33. Johansson, B.R. and Nannmark, U. (1996). Ultrastructure of interactions between activated murine natural killer cells and melanoma cells in an extracellular matrix (Matrigel) environment. Natural immunity 15, 98-106.

34. Johansson, B.R., Unger, M.L., Albertsson, P., Casselbrant, A., Nannmark, U., and Hokland, M. (1996). Infiltration and lysis of tumour cell aggregates by adherent interleukin-2-activated natural killer cells is distinct from specific cytolysis. Natural immunity 15, 87-97.

35. Palmieri, G., Gismondi, A., Galandrini, R., Milella, M., Serra, A., De Maria, R., and Santoni, A. (1996). Interaction of natural killer cells with extracellular matrix induces early intracellu-lar signalling events and enhances cytotoxic functions. Natural immunity 15, 147-153.

36. Somasundaram, R., Ruehl, M., Tiling, N., Ackermann, R., Schmid, M., Riecken, E.O., and Schuppan, D. (2000). Collagens serve as an extracellular store of bioactive interleukin 2. The journal of biological chemistry 275, 38170-38175.

37. Kuppen, P.J., Gorter, A., Hagenaars, M., Jonges, L.E., Giezeman-Smits, K.M., Nagelkerke, J.F., Fleuren, G., and van de Velde, C.J. (2001). Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model. Immunological reviews 184, 236-243.

38. Bajenoff, M., Breart, B., Huang, A.Y., Qi, H., Cazareth, J., Braud, V.M., Germain, R.N., and Glaichenhaus, N. (2006). Natural killer cell behavior in lymph nodes revealed by static and real-time imaging. The journal of experimental medicine 203, 619-631.

39. Ljunggren, H.G., and Karre, K. (1986). Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression. Opposing influences of T cell and natural killer mediated resistance? Journal of immunogenetics 13, 141-151.

40. Karre, K. (2002). NK cells, MHC class I molecules and the missing self. Scandinavian journal of immunology 55, 221-228.

41. Arnon, T.I., Markel, G., and Mandelboim, O. (2006). Tumor and viral recognition by natural killer cells receptors. Seminars in cancer biology 16, 348-358.

42. Mandelboim, O., Malik, P., Davis, D.M., Jo, C.H., Boyson, J.E., and Strominger, J.L. (1999). Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proceedings of the national academy of sciences of the United States of America 96, 5640-5644.

43. Raulet, D.H. (2003). Roles of the NKG2D immunoreceptor and its ligands. Nature reviews 3, 781-790.

44. Welte, S., Kuttruff, S., Waldhauer, I., and Steinle, A. (2006). Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nature immunology 7, 1334-1342.

45. Bryceson, Y.T., March, M.E., Ljunggren, H.G., and Long, E.O. (2006). Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107, 159-166.

46. Geldart, T. and Illidge, T. (2005). Anti-CD 40 monoclonal antibody. Leukemia & lymphoma 46, 1105-1113.

47. Arnon, T.I., Achdout, H., Levi, O., Markel, G., Saleh, N., Katz, G., Gazit, R., 111. Gonen-Gross, T., Hanna, J., Nahari, E., et al. (2005). Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nature immunology 6, 515-523.

48. Arnon, T.I., Lev, M., Katz, G., Chernobrov, Y., Porgador, A., and Mandelboim, O. (2001). Recognition of viral hemagglutinins by NKp44 but not by NKp30. European journal of immunology 31, 2680-2689.

49. Mandelboim, O., Lieberman, N., Lev, M., Paul, L., Arnon, T.I., Bushkin, Y., Davis, D.M., Strominger, J.L., Yewdell, J.W., and Porgador, A. (2001). Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409, 1055-1060.

50. Arnon, T.I., Achdout, H., Lieberman, N., Gazit, R., Gonen-Gross, T., Katz, G., Bar-Ilan, A., Bloushtain, N., Lev, M., Joseph, A., et al. (2004). The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 103, 664-672.

51. Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., et al. (1999). Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. The journal of experimental medicine 190, 1505-1516.

52. Pessino, A., Sivori, S., Bottino, C., Malaspina, A., Morelli, L., Moretta, L., Biassoni, R., and Moretta, A. (1998). Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. The journal of experimental medicine 188, 953-960.

53. Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., and Moretta, A. (1998). NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. The journal of experimental medicine 187, 2065-2072.

54. Bloushtain, N., Qimron, U., Bar-Ilan, A., Hershkovitz, O., Gazit, R., Fima, E., Korc, M., Vlodavsky, I., Bovin, N.V., and Porgador, A. (2004). Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. Journal of immunology 173, 2392-2401.

55. Costello, R.T., Sivori, S., Marcenaro, E., Lafage-Pochitaloff, M., Mozziconacci, M.J., Reviron, D., Gastaut, J.A., Pende, D., Olive, D., and Moretta, A. (2002). Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99, 3661-3667.

56. Moretta, A. (2005). The dialogue between human natural killer cells and dendritic cells. Current opinion in immunology 17, 306-311.

56. Sivori, S., Pende, D., Bottino, C., Marcenaro, E., Pessino, A., Biassoni, R., Moretta, L., and Moretta, A. (1999). NKp46 is the major triggering receptor involved in the natural cytotoxic-ity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. European journal of immunology 29, 1656-1666.

57. Carlsten, M., Bjorkstrom, N.K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B.C., Hanson, M., Schedvins, K., Kiessling, R., Ljunggren, H.G., and Malmberg, K.J. (2007). DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer research 67, 1317-1325.

58. Katz, G., Gazit, R., Arnon, T.I., Gonen-Gross, T., Tarcic, G., Markel, G., Gruda, R., Achdout, H., Drize, O., Merims, S., and Mandelboim, O. (2004). MHC class I-independent recognition of NK-activating receptor KIR2DS4. Journal of immunology 173, 1819-1825.

59. Parolini, S., Bottino, C., Falco, M., Augugliaro, R., Giliani, S., Franceschini, R., Ochs, H.D., Wolf, H., Bonnefoy, J.Y., Biassoni, R., et al. (2000). X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. The journal of experimental medicine 192, 337-346.

60. Fujii, H., Trudeau, J.D., Teachey, D., Fish, J.D., Grupp, S.A., Schultz, K.R., and Reid, G.S. (2006). In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonu-cleotides. Blood.

61. Chang, C.C. and Ferrone, S. (2006). NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Seminars in cancer biology 16, 383-392.

62. Gasser, S., Orsulic, S., Brown, E.J., and Raulet, D.H. (2005). The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186-1190.

63. Boissel, N., Rea, D., Tieng, V., Dulphy, N., Brun, M., Cayuela, J.M., Rousselot, P., Tamouza, R., Le Bouteiller, P., Mahon, F.X., et al. (2006). BCR/ABL oncogene directly controls MHC class I chain-related molecule an expression in chronic myelogenous leukemia. Journal of immunology 176, 5108-5116.

64. Coudert, J.D., Zimmer, J., Tomasello, E., Cebecauer, M., Colonna, M., Vivier, E., and Held, W. (2005). Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 106, 1711-1717.

65. Li, Z., Groh, V., Strong, R.K., and Spies, T. (2000). A single amino acid substitution causes loss of expression of a MICA allele. Immunogenetics 51, 246-248.

66. Salih, H.R., Rammensee, H.G., and Steinle, A. (2002). Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. Journal of immunology 169, 4098-4102.

67. Wu, J.D., Higgins, L.M., Steinle, A., Cosman, D., Haugk, K., and Plymate, S.R. (2004). Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. The journal of clinical investigation 114, 560-568.

68. Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., and Salih, H.R. (2006). Soluble MICA in malignant diseases. International journal of cancer 118, 684-687.

69. Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., and Salih, H.R. (2006). Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer immunology immunotherapy 55, 1584-1589.

70. Waldhauer, I. and Steinle, A. (2006). Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer research 66, 2520-2526.

71. Song, H., Kim, J., Cosman, D., and Choi, I. (2006). Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cellular immunology 239, 22-30.

72. Oppenheim, D.E., Roberts, S.J., Clarke, S.L., Filler, R., Lewis, J.M., Tigelaar, R.E., Girardi, M., and Hayday, A.C. (2005). Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nature immunology 6, 928-937.

73. Wiemann, K., Mittrucker, H.W., Feger, U., Welte, S.A., Yokoyama, W.M., Spies, T., Rammensee, H.G., and Steinle, A. (2005). Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. Journal of immunology 175, 720-729.

74. Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., and Costello, R.T. (2007). Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109, 323-330.

75. Contini, P., Ghio, M., Poggi, A., Filaci, G., Indiveri, F., Ferrone, S., and Puppo, F. (2003). Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. European journal of immunology 33, 125-134.

76. Kageshita, T., Yoshii, A., Kimura, T., Kuriya, N., Ono, T., Tsujisaki, M., Imai, K., and Ferrone, S. (1993). Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer research 53, 4927-4932.

77. Witkowska, A.M. and Borawska, M.H. (2004). Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. European cytokine network 15, 91-98.

78. Raulet, D.H., Vance, R.E., and McMahon, C.W. (2001). Regulation of the natural killer cell receptor repertoire. Annual review of immunology 19, 291-330.

79. Yokoyama, W.M., and Kim, S. (2006). How do natural killer cells find self to achieve tolerance? Immunity 24, 249-257.

80. Ito, M., Maruyama, T., Saito, N., Koganei, S., Yamamoto, K., and Matsumoto, N. (2006). Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. The journal of experimental medicine 203, 289-295.

81. Jarahian, M., Watzl, C., Issa, Y., Altevogt, P., and Momburg, F. (2007). Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. International journal of cancer.

82. Markel, G., Lieberman, N., Katz, G., Arnon, T.I., Lotem, M., Drize, O., Blumberg, R.S., Bar-Haim, E., Mader, R., Eisenbach, L., and Mandelboim, O. (2002). CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. Journal of immunology 168, 2803-2810.

83. Thies, A., Moll, I., Berger, J., Wagener, C., Brummer, J., Schulze, H.J., Brunner, G., and Schumacher, U. (2002). CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. Journal of clinical oncology 20, 2530-2536.

84. Stern, N., Markel, G., Arnon, T.I., Gruda, R., Wong, H., Gray-Owen, S.D., and Mandelboim, O. (2005). Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. Journal of immunology 174, 6692-6701.

85. Stern-Ginossar, N., Nedvetzki, S., Markel, G., Gazit, R., Betser-Cohen, G., Achdout, H., Aker, M., Blumberg, R.S., Davis, D.M., Appelmelk, B., and Mandelboim, O. (2007). Intercellular transfer of carcinoembryonic antigen from tumor cells to NK cells. Journal of Immunology 179, 4424-34.

86. Markel, G., Seidman, R., Stern, N., Cohen-Sinai, T., Izhaki, O., Katz, G., Besser, M., Treves, A.J., Blumberg, R.S., Loewenthal, R., et al. (2006). Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. Journal of immunology 177, 6062-6071.

87. Kim, S., Iizuka, K., Aguila, H.L., Weissman, I.L., and Yokoyama, W.M. (2000). In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proceedings of the national academy of sciences of the United States of America 97, 2731-2736.

88. Kim, S., Song, Y.J., Higuchi, D.A., Kang, H.P., Pratt, J.R., Yang, L., Hong, C.M., Poursine-Laurent, J., Iizuka, K., French, A.R., et al. (2006). Arrested natural killer cell development associated with transgene insertion into the Atf 2 locus. Blood 107, 1024-1030.

89. Orange, J.S. (2006). Human natural killer cell deficiencies. Current opinion in allergy and clinical immunology 6, 399-409.

90. Orange, J.S. and Ballas, Z.K. (2006). Natural killer cells in human health and disease. Clinical Immunology 118, 1-10.

91. Jeong, W.I., Park, O., Radaeva, S., and Gao, B. (2006). STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44, 1441-1451.

92. Kottilil, S., Shin, K., Jackson, J.O., Reitano, K.N., O'Shea, M.A., Yang, J., Hallahan, C.W., Lempicki, R., Arthos, J., and Fauci, A.S. (2006). Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. Journal of immunology 176, 1107-1114.

93. Lucia, B., Jennings, C., Cauda, R., Ortona, L., and Landay, A.L. (1995). Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. Cytometry 22, 10-15.

94. Richards, J.O., Chang, X., Blaser, B.W., Caligiuri, M.A., Zheng, P., and Liu, Y. (2006). Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood 108, 246-252.

95. Kashii, Y., Giorda, R., Herberman, R.B., Whiteside, T.L., and Vujanovic, N.L. (1999). Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. Journal of immunology 163, 5358-5366.

96. Yuen, M.F., Hughes, R.D., Heneghan, M.A., Langley, P.G., and Norris, S. (2001). Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver-infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma. Cancer 92, 2136-2141.

97. Kim, R., Emi, M., Tanabe, K., Uchida, Y., and Toge, T. (2004). The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100, 2281-2291.

98. Zalcenstein, A., Stambolsky, P., Weisz, L., Muller, M., Wallach, D., Goncharov, T.M., Krammer, P.H., Rotter, V., and Oren, M. (2003). Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22, 5667-5676.

99. Ivanov, V.N., Krasilnikov, M., and Ronai, Z. (2002). Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. The Journal of biological chemistry 277, 4932-4944.

100. Pikarsky, E., and Ben-Neriah, Y. (2006). NF-kappaB inhibition: a double-edged sword in cancer? European journal of cancer 42, 779-784.

101. Gray-Schopfer, V.C., Karasarides, M., Hayward, R., and Marais, R. (2007). Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer research 67, 122-129.

102. Vaupel, P., Kallinowski, F., and Okunieff, P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer research 49, 6449-6465.

103. Lardner, A. (2001). The effects of extracellular pH on immune function. Journal of leukocyte biology 69, 522-530.

104. Hellstrand, K. (2003). Melanoma immunotherapy: a battle against radicals? Trends in immunology 24, 232-233; author reply 234.

105. Nakagomi, H., Petersson, M., Magnusson, I., Juhlin, C., Matsuda, M., Mellstedt, H., Taupin, J.L., Vivier, E., Anderson, P., and Kiessling, R. (1993). Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer research 53, 5610-5612.

106. Fink, T., Ebbesen, P., Koppelhus, U., and Zachar, V. (2003). Natural killer cell-mediated basal and interferon-enhanced cytotoxicity against liver cancer cells is significantly impaired under in vivo oxygen conditions. Scandinavian journal of immunology 58, 607-612.

107. Hanna, J., Goldman-Wohl, D., Hamani, Y., Avraham, I., Greenfield, C., Natanson-Yaron, S., Prus, D., Cohen-Daniel, L., Arnon, T.I., Manaster, I., et al. (2006). Decidual NK cells regu late key developmental processes at the human fetal-maternal interface. Nature medicine 12, 1065-1074.

108. de Visser, K.E., Eichten, A., and Coussens, L.M. (2006). Paradoxical roles of the immune system during cancer development. Nature reviews cancer 6, 24-37.

109. Vitale, C., Chiossone, L., Cantoni, C., Morreale, G., Cottalasso, F., Moretti, S., Pistorio, A., Haupt, R., Lanino, E., Dini, G., et al. (2004). The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. European journal of immunology 34, 3028-3038.

110. Chiesa, M.D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., and Vitale, M. (2006). The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108, 4118-4125.

111. Mehrotra, P.T., Donnelly, R.P., Wong, S., Kanegane, H., Geremew, A., Mostowski, H.S., Furuke, K., Siegel, J.P., and Bloom, E.T. (1998). Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. Journal of immunology 160, 2637-2644.

112. Moreau, P., Adrian-Cabestre, F., Menier, C., Guiard, V., Gourand, L., Dausset, J., Carosella, E.D., and Paul, P. (1999). IL-10 selectively induces HLA-G expression in human trophob-lasts and monocytes. International immunology 11, 803-811.

113. Gonen-Gross, T., Achdout, H., Gazit, R., Hanna, J., Mizrahi, S., Markel, G., Goldman-Wohl, D., Yagel, S., Horejsi, V., Levy, O., et al. (2003). Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. Journal of immunology 171, 1343-1351.

114. Fiorentino, D.F., Zlotnik, A., Vieira, P., Mosmann, T.R., Howard, M., Moore, K.W., and O'Garra, A. (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. Journal of immunology 146, 3444-3451.

115. Mocellin, S., Ohnmacht, G.A., Wang, E., and Marincola, F.M. (2001). Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. International journal of cancer 93, 236-242.

116. Cai, G., Kastelein, R.A., and Hunter, C.A. (1999). IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. European journal of immunology 29, 2658-2665.

117. Lauw, F.N., Pajkrt, D., Hack, C.E., Kurimoto, M., van Deventer, S.J., and van der Poll, T. (2000). Proinflammatory effects of IL-10 during human endotoxemia. Journal of immunology 165, 2783-2789.

118. Salazar-Onfray, F., Petersson, M., Franksson, L., Matsuda, M., Blankenstein, T., Karre, K., and Kiessling, R. (1995). IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sen-sitive phenotype with low but peptide-inducible MHC class I expression. Journal of immunology 154, 6291-6298.

119. Huang, S., Ullrich, S.E., and Bar-Eli, M. (1999). Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. Journal of interferon & cytokine research 19, 697-703.

120. Kundu, N., Beaty, T.L., Jackson, M.J., and Fulton, A.M. (1996). Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. journal of the national cancer institute 88, 536-541.

121. Zheng, L.M., Ojcius, D.M., Garaud, F., Roth, C., Maxwell, E., Li, Z., Rong, H., Chen, J., Wang, X.Y., Catino, J.J., and King, I. (1996). Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. The journal of experimental medicine 184, 579-584.

122. Li, M.O., Wan, Y.Y., Sanjabi, S., Robertson, A.K., and Flavell, R.A. (2006). Transforming growth factor-beta regulation of immune responses. Annual review of immunology 24, 99-146.

123. Bellone, G., Aste-Amezaga, M., Trinchieri, G., and Rodeck, U. (1995). Regulation of NK cell functions by TGF-beta 1. Journal of immunology 155, 1066-1073.

124. Ortaldo, J.R., Mason, A.T., O'Shea, J.J., Smyth, M.J., Falk, L.A., Kennedy, I.C., Longo, D.L., and Ruscetti, F.W. (1991). Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. Journal of immunology 146, 3791-3798.

125. Rook, A.H., Kehrl, J.H., Wakefield, L.M., Roberts, A.B., Sporn, M.B., Burlington, D.B., Lane, H.C., and Fauci, A.S. (1986). Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. Journal of immunology 136, 3916-3920.

126. Torre-Amione, G., Beauchamp, R.D., Koeppen, H., Park, B.H., Schreiber, H., Moses, H.L., and Rowley, D.A. (1990). A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proceedings of the national academy of sciences of the United States of America 87, 1486-1490.

127. Laouar, Y., Sutterwala, F.S., Gorelik, L., and Flavell, R.A. (2005). Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nature immunology 6, 600-607.

128. Yu, J., Wei, M., Becknell, B., Trotta, R., Liu, S., Boyd, Z., Jaung, M.S., Blaser, B.W., Sun, J., Benson, D.M., Jr., et al. (2006). Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 24, 575-590.

129. Townsend, M.J., Weinmann, A.S., Matsuda, J.L., Salomon, R., Farnham, P.J., Biron, C.A., Gapin, L., and Glimcher, L.H. (2004). T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 20, 477-494.

130. Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., and Moretta, A. (2003). Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proceedings of the national academy of sciences of the United States of America 100, 4120-4125.

131. Fernandez, N.C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., and Zitvogel, L. (1999). Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature medicine 5, 405-411.

132. Borg, C., Terme, M., Taieb, J., Menard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004). Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. The journal of clinical investigation 114, 379-388.

133. Mailliard, R.B., Alber, S.M., Shen, H., Watkins, S.C., Kirkwood, J.M., Herberman, R.B., and Kalinski, P. (2005). IL-18-induced CD83+ CCR7+ NK helper cells. The journal of experimental medicine 202, 941-953.

134. Carbone, E., Terrazzano, G., Ruggiero, G., Zanzi, D., Ottaiano, A., Manzo, C., Karre, K., and Zappacosta, S. (1999). Recognition of autologous dendritic cells by human NK cells. European journal of immunology 29, 4022-4029.

135. Pende, D., Castriconi, R., Romagnani, P., Spaggiari, G.M., Marcenaro, S., Dondero, A., Lazzeri, E., Lasagni, L., Martini, S., Rivera, P., et al. (2006). Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood 107, 2030-2036.

136. Spaggiari, G.M., Carosio, R., Pende, D., Marcenaro, S., Rivera, P., Zocchi, M.R., Moretta, L., and Poggi, A. (2001). NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. European journal of immunology 31, 1656-1665.

137. Fauriat, C., Moretta, A., Olive, D., and Costello, R.T. (2005). Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. Blood 106, 2186-2188.

138. Della Chiesa, M., Vitale, M., Carlomagno, S., Ferlazzo, G., Moretta, L., and Moretta, A. (2003). The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. European journal of immunology 33, 1657-1666.

139. Moretta, L., Ferlazzo, G., Bottino, C., Vitale, M., Pende, D., Mingari, M.C., and Moretta, A. (2006). Effector and regulatory events during natural killer-dendritic cell interactions. Immunological reviews 214, 219-228.

140. Marcenaro, E., Della Chiesa, M., Bellora, F., Parolini, S., Millo, R., Moretta, L., and Moretta, A.

(2005). IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. Journal of immunology 174, 3992-3998.

141. Vitale, M., Della Chiesa, M., Carlomagno, S., Pende, D., Arico, M., Moretta, L., and Moretta, A. (2005). NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 106, 566-571.

142. Vitale, M., Della Chiesa, M., Carlomagno, S., Romagnani, C., Thiel, A., Moretta, L., and Moretta, A. (2004). The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. European journal of immunology 34, 1715-1722.

143. Adam, C., King, S., Allgeier, T., Braumuller, H., Luking, C., Mysliwietz, J., Kriegeskorte, A., Busch, D.H., Rocken, M., and Mocikat, R. (2005). DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 106, 338-344.

144. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., and Nakayama, E. (1999). Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer research 59, 3128-3133.

145. Shimizu, J., Yamazaki, S., and Sakaguchi, S. (1999). Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. Journl of immunology 163, 5211-5218.

146. Ghiringhelli, F., Puig, P.E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., and Zitvogel, L. (2005). Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+ CD25+ regulatory T cell proliferation. The Journal of experimental medicine 202, 919-929.

147. Nishikawa, H., Kato, T., Tawara, I., Takemitsu, T., Saito, K., Wang, L., Ikarashi, Y., Wakasugi, H., Nakayama, T., Taniguchi, M., et al. (2005). Accelerated chemically induced tumor development mediated by CD4+ CD25+ regulatory T cells in wild-type hosts. Proceedings of the national academy of sciences of the United States of America 102, 9253-9257.

148. Trzonkowski, P., Mysliwska, J., Szmit, E., Wieckiewicz, J., Lukaszuk, K., Brydak, L.B., Machala, M., and Mysliwski, A. (2003). Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the antiinfluenza vaccination-an impact of immunosenescence. Vaccine 21, 3826-3836.

149. Wolf, A.M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., and Grubeck-Loebenstein, B. (2003). Increase of regulatory T cells in the peripheral blood of cancer patients. Clinical cancer research 9, 606-612.

150. Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P.E., Novault, S., Escudier, B., Vivier, E., et al. (2005). CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. The journal of experimental medicine 202, 1075-1085.

151. Morse, M.A., Garst, J., Osada, T., Khan, S., Hobeika, A., Clay, T.M., Valente, N., Shreeniwas, R., Sutton, M.A., Delcayre, A., et al. (2005). A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. Journal of translational medicine 3, 9.

152. Smyth, M.J., Teng, M.W., Swann, J., Kyparissoudis, K., Godfrey, D.I., and Hayakawa, Y.

(2006). CD4+ CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. Journal of immunology 176, 1582-1587.

153. Barao, I., Hanash, A.M., Hallett, W., Welniak, L.A., Sun, K., Redelman, D., Blazar, B.R., Levy, R.B., and Murphy, W.J. (2006). Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+ CD25+ regulatory T cells. Proceedings of the national academy of sciences of the United States of America 103, 5460-5465.

154. Oida, T., Zhang, X., Goto, M., Hachimura, S., Totsuka, M., Kaminogawa, S., and Weiner, H.L. (2003). CD4+ CD25- T cells that express latency-associated peptide on the surface suppress CD4+ CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. Journal of immunology 170, 2516-2522.

155. Liu, C., Yu, S., Kappes, J., Wang, J., Grizzle, W.E., Zinn, K.R., and Zhang, H.G. (2007). Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor bearing host. Blood.

156. Gorelik, E., Bere, W.W., and Herberman, R.B. (1984). Role of NK cells in the antimetastatic effect of anticoagulant drugs. International journal of cancer 33, 87-94.

157. Rickles, F.R., and Edwards, R.L. (1983). Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62, 14-31.

158. Gunji, Y. and Gorelik, E. (1988). Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer research 48, 5216-5221.

159. Nierodzik, M.L., Plotkin, A., Kajumo, F., and Karpatkin, S. (1991). Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. The journal of clinical investigation 87, 229-236.

Was this article helpful?

0 0
Beating The Butt On Your Own

Beating The Butt On Your Own

Need To Stop Smoking? Are You Willing To Follow My Powerful Strategies To Stop Smoking And Vividly Transform Your Life Today? Proven Tips, Tools and Tactics To Stop Smoking And Live An Awesome Life You Always Wanted.

Get My Free Ebook


Post a comment